Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00624884
Other study ID # YT1977
Secondary ID
Status Completed
Phase N/A
First received February 19, 2008
Last updated June 27, 2008
Start date March 2008
Est. completion date May 2008

Study information

Verified date June 2008
Source Florence Nightingale Hospital, Istanbul
Contact n/a
Is FDA regulated No
Health authority Turkey: Ministry of Health; Turkey: Ethics Committee
Study type Observational

Clinical Trial Summary

Velocity Vector Imaging may provide reliable and detailed information on left ventricular segmental function in asymptomatic patients with moderate-to severe AR. This may help to identify subclinical myocardial dysfunction in order to operate early enough to prevent postoperative heart failure and restrict unnecessary early operation which could be associated with operative risks and mortality related to prosthetic valves.


Description:

Chronic aortic regurgitation (AR) is a progressive process which causes both left ventricular volume and pressure overload. While the volume overload is associated with the degree of the aortic regurgitant volume, the pressure overload occurs as a result of systemic hypertension developed due to increased stroke volume. In early stages, excentric hypertrophy occurs aiming to compensate the volume overload in the left ventricle. Therefore , ejection fraction remains in normal range despite the increasing volume overload. Left ventricular dilatation and impairment in ejection fraction only occur in the end stages of the disease. Asymptomatic patients with chronic aortic regurgitation (AR) have a good prognosis in the presence of preserved systolic function. Therefore it is a challenge to identify patients with subclinical left ventricular (LV) dysfunction. Velocity vector imaging (VVI) is a new echocardiographic method based on two dimensional gray scale imaging, which is angle independent and can provide more accurate data about cardiac function.


Recruitment information / eligibility

Status Completed
Enrollment 50
Est. completion date May 2008
Est. primary completion date April 2008
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

- Moderate-to-severe aortic regurgitation identified by Standard echocardiography.

- Chronic isolated aortic regurgitation

- Being asymptomatic ( Class 1 according to NYHA)

- Sinusal rhythm

Exclusion Criteria:

- Ejection fraction < 50%

- Mitral valve disease accompanied to aortic regurgitation (patients with over mild degree of mitral regurgitation and stenosis

- Aortic stenosis

- Previous myocardial infarction, or the patients with >50% coronary occlusion in any of the coronary arteries.

- Cardiomyopathies

- AV conduction disorders

- Chronic renal or hepatic insufficiency

- Malignities

Study Design

Observational Model: Case Control, Time Perspective: Prospective


Related Conditions & MeSH terms


Locations

Country Name City State
Turkey TC.Istanbul Bilim University, Florence Nightingale Hospital, Division of Cardiology Istanbul Sisli

Sponsors (1)

Lead Sponsor Collaborator
Florence Nightingale Hospital, Istanbul

Country where clinical trial is conducted

Turkey, 

References & Publications (1)

Sokmen G, Sokmen A, Duzenli A, Soylu A, Ozdemir K. Assessment of myocardial velocities and global function of the left ventricle in asymptomatic patients with moderate-to-severe chronic aortic regurgitation: a tissue Doppler echocardiographic study. Echocardiography. 2007 Jul;24(6):609-14. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Velocity Vector Imaging derived segmental systolic peak Strain and Strain rates April 2008 No
See also
  Status Clinical Trial Phase
Completed NCT03314857 - China XT: Safety and Effectiveness of Edwards Lifesciences SAPIEN XT THV in the Chinese Population N/A
Completed NCT03666351 - Study to Evaluate the Effect on Improvement of LVH by the Control of BP in Hypertension Patients With AV Disease Phase 4
Recruiting NCT06034028 - J-Valve TF Early Feasibility Study N/A
Completed NCT05515848 - Aortic Valve-sparing Root Replacement, According to the Inclusion Technique Described by Tirone David
Active, not recruiting NCT03549091 - Accuracy of Left Subclavian Regurgitation Evaluated by Ultrasound Doppler and 4D Flow MRI N/A
Completed NCT01598844 - JUPITER Study: Transapical Aortic Valve Implantation for Aortic Regurgitation
Active, not recruiting NCT03466918 - China S3: Safety and Effectiveness of Edwards Lifesciences SAPIEN 3 THV in the Chinese Population N/A
Active, not recruiting NCT04415047 - The JenaValve ALIGN-AR Pivotal Trial N/A
Not yet recruiting NCT05319171 - Performance of Currently Available traNscaTHEter Aortic Valve Platforms in Inoperable Patients With Pure Aortic regurgitatiON of a Native Valve. The PANTHEON International Project.
Completed NCT05774795 - LOng-Term Fate of Moderate Aortic Regurgitation Left Untreated at the Time of Mitral Valve Surgery
Terminated NCT02351726 - Mitroflow DL Post Approval Study- North America N/A
Withdrawn NCT05409378 - HLT® Meridian® TAVR Valve System Early Feasibility Study for Aortic Regurgitation N/A
Recruiting NCT04038879 - Comparison Study of Echocardiography and Cardiovascular Magnetic Resonance Imaging in the Assessment of Mitral and Aortic Regurgitation
Completed NCT05332184 - Cardiac T1 Mapping Enables Risk Prediction of LV Dysfunction After Surgery for Aortic Regurgitation
Completed NCT01400841 - HAART Model 300 Annuloplasty Ring N/A
Not yet recruiting NCT02633423 - Expiratory Flow Limitation and Mechanical Ventilation During Cardiopulmonary Bypass in Cardiac Surgery N/A
Completed NCT00976625 - Diastolic Dysfunction in Aortic Regurgitation N/A
Enrolling by invitation NCT05714293 - CT-evaluation of Coronary Ostia Height After Surgical Aortic Valve Replacement. N/A
Recruiting NCT02974920 - Rivaroxaban or Aspirin for Biological Aortic Prosthesis Phase 4
Not yet recruiting NCT03788590 - Evaluate the Transcatheter Artificial Aortic Valve and Transcatheter Artificial Heart Values Delivery System N/A